ImmunityBio, Inc. (IBRX) Financials

IBRX Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 628.5 million 1.7 billion
March 31, 2026 646.6 million 1.5 billion
Dec. 31, 2025 501.9 million 1.0 billion
Sept. 30, 2025 519.0 million 1.0 billion

IBRX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -147.1 million 16.7 million
March 31, 2026 -77.1 million 8.2 million
Dec. 31, 2025 -71.7 million 8.7 million
Sept. 30, 2025 -69.7 million 8.9 million

IBRX Net Income

No data available :(

IBRX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 357.4 million 31.2 million 31.2 million
March 31, 2026 380.9 million 1.1 billion 41.0 million
Dec. 31, 2025 242.8 million 835.2 million 33.7 million
Sept. 30, 2025 257.8 million 500.8 million 41.7 million

IBRX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 1.1 billion
March 31, 2026 1.0 billion
Dec. 31, 2025 989.7 million
Sept. 30, 2025 946.6 million

IBRX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 5.3 million 57.7 million 50.6 million -
March 31, 2026 1.8 million 64.8 million 44.5 million -
Dec. 31, 2025 1.3 million 60.8 million 37.8 million -
Sept. 30, 2025 775000 50.7 million 32.8 million -

IBRX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 51.2 million 298000
March 31, 2026 44.2 million 238000
Dec. 31, 2025 38.3 million 4.2 million
Sept. 30, 2025 32.1 million 4.1 million

IBRX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

IBRX

Price: $7.95

52 week price:
1.95
12.43

Payout Ratio Range:
-5.66%
-4.71%

Earnings Per Share: -0.95 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.2 million

Market Capitalization: 8.1 billion

Links: